263 reports of this reaction
4.0% of all FINGOLIMOD reports
#3 most reported adverse reaction
MULTIPLE SCLEROSIS is the #3 most commonly reported adverse reaction for FINGOLIMOD, manufactured by Apotex Corp.. There are 263 FDA adverse event reports linking FINGOLIMOD to MULTIPLE SCLEROSIS. This represents approximately 4.0% of all 6,602 adverse event reports for this drug.
Patients taking FINGOLIMOD who experience multiple sclerosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE SCLEROSIS is moderately reported among FINGOLIMOD users, representing a notable but not dominant share of adverse events.
In addition to multiple sclerosis, the following adverse reactions have been reported for FINGOLIMOD:
The following drugs have also been linked to multiple sclerosis in FDA adverse event reports:
MULTIPLE SCLEROSIS has been reported as an adverse event in 263 FDA reports for FINGOLIMOD. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE SCLEROSIS accounts for approximately 4.0% of all adverse event reports for FINGOLIMOD, making it one of the most commonly reported side effect.
If you experience multiple sclerosis while taking FINGOLIMOD, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.